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Abstract
Background—Anemia is associated with decreased functional capacity, reduced quality of life,
and worsened outcomes among patients with heart failure (HF) due to reduced left ventricular
ejection fraction (HFREF). We sought to evaluate the independent effect of anemia on clinical
outcomes among those with HFREF.
Methods—The HF-ACTION trial was a prospective, randomized trial of exercise therapy versus
usual care in 2331 patients with HFREF. Patients with New York Heart Association class 2–4 HF
and left ventricular ejection fractions of ≤ 35% were recruited. Hemoglobin (Hb) was measured up
to one year prior to entry and was stratified by quintile. Anemia was defined as baseline Hb < 13
g/dl and <12 g/dl in men and women, respectively. Hb was assessed in two models; a global
prediction model that had been previously developed and a modified model including variables
associated with anemia and the studied outcomes.
Results—Hemoglobin was available at baseline in 1763 subjects (76% of total study
population); their median age was 59.0 years, 73% were male, and 62% were Caucasian. The
prevalence of anemia was 515/1763 (29%). Older age, female gender, African American race,
diabetes, hypertension, and lower estimated glomerular filtration rates were all more frequent in
lower Hb quintiles. Over a median follow-up of 30 months, the primary outcome of all-cause
mortality or all-cause hospitalization occurred in 78% of those with anemia and 64% in those
without, p<0.001. The secondary outcomes of all-cause mortality alone, cardiovascular mortality
or cardiovascular hospitalization, and cardiovascular mortality or HF hospitalization occurred in
23 % vs 15%, 67% vs 54%, and 44 vs 29%, respectively, p<0.001. Heart failure hospitalizations
occurred in 36% vs 22%, and urgent outpatient visits for HF exacerbations occurred in 67% and
55%, respectively, p<0.001. For the global model, there was an association observed for anemia
and all-cause mortality or hospitalization, adjusted hazard ratio (HR)=1.15, 95% CI 1.01–1.32,
p=0.04, but other outcomes were not significant at p<0.05. In the modified model, the adjusted HR
for anemia and the primary outcome of all-cause mortality or all-cause hospitalization was 1.25,
95% CI 1.10–1.42, p<0.001. There were independent associations between anemia and all-cause
death, HR=1.11, 95% CI 0.87–1.42, p=0.38; cardiovascular death or cardiovascular
hospitalization, HR=1.16, 95% CI 1.01–1.33, p=0.035; and cardiovascular death and heart failure
hospitalization, HR=1.27, 95% CI 1.06–1.51, p=0.008.
Conclusions—Anemia modestly is associated with increased rates of death, hospitalization, and
HF exacerbation in patients with chronic HFREF. After adjusting for other important covariates,
anemia is independently associated with an excess hazard for all-cause mortality and all-cause
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hospitalization. Anemia is also associated with combinations of cardiovascular death and
cardiovascular/heart failure hospitalizations as composite endpoints.
Keywords
heart failure; chronic kidney disease; anemia; glomerular filtration rate; renal insufficiency;
hospitalization; mortality
Both heart failure (HF) and chronic kidney disease (CKD) are increasing in prevalence as
the population ages, and both conditions have been associated with anemia of chronic
disease.1 2 Common risk factors for both CKD and HF include obesity, metabolic
syndrome, diabetes, and hypertension, some of which are commonly linked with the
development of anemia.3 4 5 6 Previous HF studies have consistently reported an
association between reduced estimated glomerular filtration rates (eGFR), anemia, elevated
levels of B-type natriuretic peptide, and increased HF mortality. 7 8 9 Anemia, even in the
absence of renal disease, has also been associated with adverse clinical outcomes; however
the impact of HF, anemia, and CKD, alone or in combination on mortality, adverse events,
and hospitalization rates, remains of clinical interest.10 It is not certain whether the adverse
effect of anemia on clinical outcomes is independent of its impact on other comorbid
conditions. Of note, anemia in HF may be dynamic; when hemoglobin (Hb) rises, there have
been favorable changes in left ventricular mass and improved symptoms.11 We sought to
evaluate the impact of baseline anemia on the composite outcome of all-cause death and all-
cause hospitalization and various cardiovascular and HF outcomes among patients with
chronic systolic HF participating in the HF-ACTION trial.
Methods
Setting
Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training (HF-
ACTION) was a prospective, randomized trial of aerobic exercise training in patients who
were medically stable, with New York Heart Association (NYHA) classes II to IV HF and
measured left ventricular ejection fraction ≤ 35%. Recruitment criteria and methods for HF-
ACTION have been reported elsewhere.12 13 Major exclusion criteria were comorbidities
that may have precluded moderate-to-vigorous intensity exercise (e.g. peritoneal or
hemodialysis) and major cardiovascular events within the last six months. The trial was
designed to evaluate the composite primary end point of all-cause mortality and all-cause
hospitalization over a median follow-up of 30 months in patients who were optimally
medically managed and underwent medically supervised and home-based exercise training
as compared with controls who received usual care.13 Primary and secondary endpoints
were adjudicated by a clinical endpoints committee. Once a subject incurred one
hospitalization for heart failure, subsequent hospitalizations were not reviewed by the end-
point committee and were classified according to the indication by the principal investigator.
Study Sample
A total of 2331 subjects were recruited from April, 2003, through February, 2007, at 82 sites
within the United States, Canada, and France; however, the study sample was reduced
McCullough et al. Page 3
Clin Cardiol. Author manuscript; available in PMC 2014 October 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
because 568 subjects had no measured Hb recorded at baseline. The remaining 1763 (76%
of the total trial population) served as the study sample, providing complete data for
analysis.
Laboratory Measures and Calculation of Glomerular Filtration Rate
Hemoglobin and serum creatinine (SCr) were obtained from the reported values from the
study sites recorded within one year prior to trial enrollment and performed by the local
laboratory at each center. Detailed methods for local measurement of Hb and SCr were no
available. Anemia was defined as a baseline Hb <13 g/dl and <12 g/dl in men and women
(World Health Organization definition), respectively.14 Estimated glomerular filtration rates
(eGFR ml/min/1.73 m2) were calculated using the four-variable Levey Modification of Diet
in Renal Disease formula (186.3*[SCr- 1.154]*[age-.203]); calculated values were
multiplied by 0.742 for women and by 1.21 for African Americans.15
Statistical Analysis
Statistical analyses were performed by the data coordinating center (Duke Clinical Research
Institute, Durham, NC) using SAS software version 9.2 (SAS Institute Inc., Cary, NC).
Baseline characteristics were reported as medians with 25th and 75th percentiles, or counts
and proportions as appropriate. The primary composite end point was all-cause mortality or
hospitalization. Pre-specified secondary end points were all-cause mortality, cardiovascular
mortality or cardiovascular hospitalization, and cardiovascular mortality or heart failure
hospitalization. Cumulative event rates were calculated using the Kaplan-Meier method.
Time zero for censoring was the time of randomization. Relative risks were expressed as
hazard ratios (HR) with 95% confidence intervals and were calculated using the Cox
proportional hazards model. Two modeling approaches were taken. Model 1 was created a
priori to predict each of the four main clinical endpoints using the entire 2331 subjects
recruited into HF-ACTION with the goal of creating an adjustment model. For this method,
included variables were identified via a bootstrapped backwards selection algorithm of a
Cox proportional hazards model with the C-index used to choose the best model for each
outcome (see appendix). This approach evaluated 61 candidate variables (including Hb) and
was done independent and before the current analysis. This analysis did not identify Hb as a
strong predictor of outcomes. After reviewing Model 1 results and the included covariates it
was decided to create a model (Model 2) which focused on evaluating specifically whether
anemia was a predictor of outcomes and included only the 1763 subjects with actual, non-
imputed Hb values. Model 2 used variables found to be differentially associated with Hb
(Table 1) and known to be clinical confounders for HF including: age, African American
versus other race, female gender, diabetes mellitus, ischemic etiology of HF, LVEF, and
eGFR. Other variables in the HF-ACTION database excluded from Model 2 were those
believed to result from anemia or related to other included variables (exercise performance
variables, quality of life, and symptom scores), variables known to be confounded by
indication (e.g. beta-blocker and diuretic dosage, use of nitrates), biologic representations of
the same construct (e.g. SCr and blood urea nitrogen where renal filtration function
represented by eGFR) and those with no biologic plausibility (randomization allocation, site
of randomization). The univariate relationship of the continuous variables in this set (age,
LVEF, eGFR) with each outcome was checked for linearity of the log HR, and piecewise
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linear splines were used as transformations when appropriate in Model 2. A two-tailed p-
value < 0.05 was considered statistically significant.
Results
Baseline Characteristics
Selected demographics for the study sample (n=1763) were as follows: median age 59 years
(range 19–90); 73% male; 62% Caucasian, 33% African American and 5% other races
(Table 1). The overall prevalence of anemia was 30.1% and 26.9% in men and women,
respectively. The median Hb was 15.6 g/dl for Q5 compared to 11.4 g/dl for Q1. At
baseline, we found that in patients with HFREF, reduced Hb was more frequent among the
expected conditions including older age, female gender, African Americans diabetes,
hypertension, and mildly reduced renal filtration function. In the lowest quintile of Hb, the
median eGFR was 59 with an interquartile range of 44–76 ml/kg/1.73 m2. Thus, nearly all
subjects were above critical levels of renal dysfunction. The most striking contrast was a
prevalence of diabetes corresponding to 40% in Q1 compared to 27% in Hb Q5.
Adverse Events
The median follow-up times for those with and without anemia were 30 and 31 months,
respectively, p=0.594. Table 2 displays selected adverse events reported by site investigators
over the course of the trial according to the presence of anemia. These adverse events were
not adjudicated by the endpoints committee nor adjusted for confounding variables. With the
exception of transient ischemic attack, adverse events were more frequent for those with
anemia. The fraction of subjects with at least one selected adverse cardiovascular event was
49% and 37%, respectively, for those with and without anemia.
Prespecified Primary and Secondary Outcomes in the Trial
Kaplan-Meier curves for the prespecified primary and secondary endpoints are shown in
Figures 2–4. Individual trial outcomes and unadjusted/adjusted HRs for subjects with and
without anemia are shown in Table 3. Over the median follow-up of 30 months, all-cause
mortality or all-cause hospitalization occurred in 78% vs 64%, and all-cause mortality alone
occurred in 23% vs 15% among patients with and without anemia, respectively, p<0.001 for
both. Cardiovascular mortality or cardiovascular hospitalization and cardiovascular
mortality or heart failure hospitalization occurred in 67% vs 54%, and 44% vs 29%,
respectively, p<0.001 in those with and without anemia. HF hospitalizations occurred in
36% vs 22%, and urgent outpatient visits for HF exacerbations in 67% vs 55%, in the
anemia versus no anemia groups respectively, p<0.001 for both. Kaplan-Meier curves
demonstrating the time to first event are shown in Figure 1 for all-cause mortality or all-
cause hospitalization as a composite. The results from univariate and multivariate
adjustment Models 1 and 2 are shown in Table 3. For Model 1, the adjusted hazards ratio for
anemia and the primary outcome of all cause mortality or all-cause hospitalization was 1.15
(CI 1.01–1.32), p=0.042. The adjusted hazards for anemia and the prespecified secondary
outcomes were 0.99 (95% CI 0.77–1.27), p=0.919 for all-cause death; 1.22 (95% CI 0.97–
1.30), p=0.120 for cardiovascular death or cardiovascular hospitalization; and 1.20 (95% CI
0.99–1.44), p=0.060 for cardiovascular death and heart failure hospitalization. For the
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modified model designed to evaluate anemia as a predictor of outcomes, the adjusted
hazards ratio for anemia and the primary outcome of all cause mortality or all-cause
hospitalization was 1.25 (95% CI 1.10–1.42), p<0.001. The adjusted hazards for anemia and
the prespecified secondary outcomes were 1.11 (95% CI 0.87–1.42), p=0.385 for all-cause
death; 1.16 (95% CI 1.01–1.33), p=0.035 for cardiovascular death or cardiovascular
hospitalization; and 1.27 (95% CI 1.06–1.51), p=0.008 for cardiovascular death and heart
failure hospitalization. All of these analyses demonstrated attenuation of the measure of
association with adjustment, and this attenuation was greater for the global model (Model 1)
than when adjusting for specific confounders of the anemia and outcomes association using
Model 2 (i.e. age, African American versus other race, female gender, diabetes mellitus,
ischemic etiology of HF, LVEF, and eGFR).
Discussion
The current analysis provides a unique opportunity to evaluate the relationship of anemia to
outcomes in stable HF patients with preserved eGFR. In general, all the unadjusted hazards
for trial endpoints were elevated for those with anemia. There were no indications of
competing risks given the similar follow-up times for those with and without anemia
(median 30 months for each, Table 2). For both the original predictive model developed for
the primary endpoint and the modified model, anemia was associated with the primary
endpoint of time to all-cause mortality or hospitalization. Although the association with
other trial outcomes were non-significant in the global model, these associations were
evident for the primary and secondary outcomes when the model was modified to be more
specific to an evaluation of anemia. These data are consistent with the notion that anemia,
even in those with only mildly reduced or normal renal function, is an elevated risk state for
patients with HFREF and represents a complicated clustering of modulators that are related
to cardiac mortality or hospitalization.29 Anemia may be both a contributor and a result of
HF as a chronic disease state. Reduced Hb is associated with impaired oxygen delivery, salt
and water retention, and chronic volume overload which may exacerbate HF symptoms.28 It
has been reported in clinical trials and observational studies that patients with the lowest Hb
values have higher physician assigned NYHA class and worse HF symptoms.28
Additionally, anemia has been consistently associated with higher rates of hospitalization for
heart failure and other causes as well as all-cause mortality in those with HF.19 20 Anemia
can be considered a manifestation of the chronic cardiorenal syndrome, where either the HF
worsens kidney function (Type 2) or vice versa (Type 4).21 In cardiorenal syndromes,
anemia may play a role in reducing oxygen delivery, thus impairing myocardial contractility
and systolic performance.22 In addition, increased LV mass is commonly associated with
anemia and progressive renal failure and may be related to the impairment of cellular
transport of electrolytes and oxygen which mechanical and metabolic functions.23 Chronic
kidney disease and HF have been associated with increased levels of hepcidin-25, which
inhibits the ferroportin transporter and blocks iron transport from the gut and at many
somatic levels.24 In addition, reduced renal mass is associated with relative deficiency of
erythropoietin, which is partially responsible for the predictable decline in erythroid mass as
renal function declines. Moreover, deficient levels of erythropoietin may directly influence
left ventricular remodeling and HF. 25 Lastly, anemia is associated with increased markers
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of inflammation and oxidative stress.26 27 Collectively, these pathologic changes may be
responsible, for the higher morbidity and mortality associated with anemia in HFREF that
we reported in HF-ACTION and has been observed in other studies.28
Our study adds to the literature in demonstrating that anemia, even at higher levels of eGFR
at baseline is independently associated with an array of adverse outcomes including cardiac
and all-cause hospitalization, emergency department visit, or urgent clinic visit for heart
failure exacerbation, and death due to heart failure or other cardiac causes.
We recognize that both renal filtration function and older age are important confounders in
the relationship between anemia and poor outcomes.29 30 Herzog and colleagues found
among Medicare recipients not on dialysis, that the annual mortality rates were: 4% for
those with no HF, CKD, 8% for anemia or CKD, 13% for HF, and 23% for all three
conditions in the same patient population.31 The annual mortality rate in HF ACTION was
< 10%, suggesting selection bias for the trial significantly reduced generalizability and may
have reduced the relative impact of anemia on survival. Thus, both in community
populations and clinical trials, senescent decline in both bone marrow and renal function
may play a role in cardiac adverse events precipitating hospitalization, and in some
circumstances, contributing to death.32 33
Our findings suggested that investigator reported adverse events related to the heart were
more frequent in those with anemia. Finally, the triad of older age, anemia, and reduced
renal function may identify a particularly frail population that is more prone to medication
adverse events, complications with invasive procedures, and a greater susceptibility to
event-driven mortality over the natural history of HF.34 35
Limitations
Our study has all the limitations of a post-hoc analysis from a large randomized trial.
Selection bias for entry into the trial of exercise training yielded a younger and more robust
group of HF patients able to exercise which may not represent those commonly seen in
clinical practice. We did not have baseline hemoglobin or creatinine values on all the
subjects in the trial; thus, this is a subgroup that has both measures recorded on the case
report form up to one year prior to randomization. We did not have a background history of
prior anemia or its treatments including iron or erythrocyte stimulating agents. Because
subjects were restricted to having systolic HF, we cannot generalize our findings to those
with more modestly reduced LVEF (36–45%) or to those with preserved systolic function.
Hemoglobin and SCr values were obtained from clinical records and not measured in a core
laboratory. Thus, differences in assay types and standardization probably contributed to
variation in eGFR. Furthermore, we did not measure arterial blood gases, serum iron indices,
folate, vitamin B12, or erythropoietin precluding the etiology of anemia. Lastly, we did not
have measures of iron transport, inflammation, and oxidative stress or other biomarkers to
elucidate the pathophysiologic mechanisms relating chronic failure of the heart, bone
marrow, and kidneys.36 The current analysis provides results from two models, which both
have limitations. Model 1 was derived a priori from the complete cohort. Hb values were
missing in 24% of the cases and were imputed in order to be included in the preconstructed
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global model (Model 1). Derived variables integrating information such as eGFR or anemia
as defined as a disease state in this paper were not considered at the time Model 1 was
created. Model 1 also did not allow clinical refinement for multicollinearity and did not
exclude potential symptomatic outcomes of anemia as predictors. Additionally, since Model
1 had a large number of predictor variables relative to the number of outcomes, it was
subject to over-fitting and over-adjustment. While Model 2 addressed some of the
shortcomings of Model 1, it excluded known predictors of clinical outcomes in heart failure
featured in other HF-ACTION papers, including peak VO2, quality of life, medication
treatment, and detailed echocardiographic measures. Model 2 was created based upon
univariate findings and after Model 1 results were known. Both models have the limitation
of unknown or unmeasured confounders that may account for the association between
anemia and the clinical outcomes reported.
Conclusion
Anemia is associated with increased rates of death, hospitalization, and HF exacerbation in
outpatients with chronic HFREF and with both preserved and decreased renal filtration
function. After adjusting for other important covariates, anemia is independently associated
with an excess hazard for all-cause mortality and all-cause hospitalization. Anemia is also
associated with combinations of cardiovascular death and cardiovascular/heart failure
hospitalizations as composite endpoints.
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Figure 1.
Time to all-cause mortality or all-cause hospitalization stratified by the presence or absence of anemia, numbers at risk include
only those with nonmissing covariates (total is less than 1763)
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Figure 2.
Time to all-cause mortality stratified by the presence or absence of anemia, numbers at risk include only those with nonmissing
covariates (total is less than 1763)
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Figure 3.
Time to CV mortality or CV hospitalization, stratified by the presence or absence of anemia, numbers at risk include only those
with nonmissing covariates (total is less than 1763)
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Figure 4.
Time to CV mortality or HF hospitalization, stratified by the presence or absence of anemia, numbers at risk include only those
with nonmissing covariates (total is less than 1763)
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Table 2
Selected adverse outcomes according to presence or absence of anemia, N (%)
All Anemia No Anemia
N 1763 515 1248
Median Follow-up (median, 25 and 75 percentiles in months) 30 (19–42) 30 (18–43) 31 (20–42)
Prespecified Adverse Cardiovascular Events
Worsening Heart Failure 518 (29) 200 (39) 318 (25)
Unstable angina 138 (7.8) 51 (9.9) 87 (7.0)
Serious arrhythmia 261 (15) 82 (16) 179 (14)
Stroke 52 (2.9) 22 (4.3) 30 (2.4)
Transient ischemic attack 30 (1.7) 7 (1.4) 23 (1.8)
Any of the above events 711 (40) 253 (49) 458 (37)
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